UNH Q3 beat-and-raise: adj EPS $4.69 vs ~$4.12–4.15 est, MCR 88.4%, FY26 adj EPS now "at least $20.50" — call 13:00 Lond

[LondonNewsTrader]

UnitedHealth was first out of the gate this morning (10:55 London) and it reads as a clean beat-and-raise on the headline numbers.

What they reported for Q3:
- Revenue $112.7B vs roughly $111.3–111.4B expected
- Adjusted EPS $4.69 (GAAP $4.56) vs consensus around $4.12–4.15
- Medical care ratio 88.4% vs 89.9% a year ago
- Operating cost ratio 12.8% vs 13.5% a year ago
- Full-year 2026 adjusted EPS now "at least $20.50" (GAAP at least $19.50). The July guide was $19.50–20.00.

The detail I'd keep in mind before chasing anything:
- The MCR includes $610M of favourable prior-period reserve development (2026 dates of service). Q2 had $860M of the same. So part of the cost "improvement" is reserve releases, and the call will be about how much of it is repeatable.
- For reference, the full-year MCR guide coming out of Q2 was 88.1% ± 25 bp. Any update to that range on the call matters more than the EPS beat.
- Options were pricing roughly a 6.5–7% move into the print. UNH has a history of big gaps on earnings, in both directions.

For the tape:
- Conference call is 8:00 ET / 13:00 London. Expect pre-market to whip around while management talks MCR, Medicare Advantage and Optum.
- Managed-care names (HUM, CVS, ELV, CNC) usually trade in sympathy. HUM is already in play from the Star Ratings story last week.
- Personally I'd let the first 5–15 minutes of cash set the range rather than trade the pre-market gap blind, given how thin the early book can be.

Source: [UnitedHealth Q3 2026 release](https://au.marketscreener.com/news/unit ... dddc8ff026)

Anyone trading UNH off the open, or are you sticking to the bank prints this morning? And do you discount the reserve-release part of the beat, or does the market not care as long as the guide goes up?